Related Experiment Videos
Scintigraphic detection of xenografted tumors producing human basic fibroblast growth factor
H Kobayashi1, H Sakahara, M Hosono
1Department of Nuclear Medicine, Faculty of Medicine, Kyoto University, Japan.
Abstract:
A murine monoclonal antibody 3H3 recognizes the basic fibroblast growth factor (FGF) and inhibits the growth of human glioblastoma cells both in vitro and in vivo. We studied the potential of a scintigraphic technique using the 3H3 antibody to detect tumors that produce basic FGF. 125I- and 111In-labeled 3H3 bound to U87MG human glioblastoma cells in vitro. U87MG cells were inoculated subcutaneously into nude mice. After development of the tumor, radiolabeled 3H3 was injected into the subcutaneous space surrounding the tumor. A high level of radioactivity from 3H3 was retained at the tumor, whereas an irrelevant antibody cleared rapidly from the injected site. Radiolabeled 3H3 was not retained in tumors that did not produce basic FGF. Scintigraphic detection of tumors expressing basic FGF would be valuable for the therapeutic application of the antibody.
Insights
A novel antibody (3H3) can detect tumors producing basic fibroblast growth factor (FGF). This antibody shows potential for scintigraphic tumor imaging, aiding in therapeutic applications.
Area of Science:
- Oncology
- Immunology
- Radiochemistry
Background:
- Glioblastoma is an aggressive brain tumor.
- Basic fibroblast growth factor (FGF) plays a role in glioblastoma growth.
- Targeting FGF with monoclonal antibodies is a potential therapeutic strategy.
Purpose of the Study:
- To evaluate the potential of a murine monoclonal antibody, 3H3, for scintigraphic detection of tumors producing basic FGF.
- To assess the efficacy of radiolabeled 3H3 in localizing and detecting tumors expressing basic FGF.
Main Methods:
- In vitro studies involved labeling 3H3 antibody with Iodine-125 (125I) and Indium-111 (111In) and assessing its binding to U87MG human glioblastoma cells.
- In vivo studies utilized nude mice with subcutaneous U87MG tumors. Radiolabeled 3H3 was administered, and its retention at the tumor site was compared to an irrelevant antibody.
- Tumor detection was evaluated based on the retention of radioactivity in tumors that did and did not produce basic FGF.
Main Results:
- 125I- and 111In-labeled 3H3 demonstrated binding to U87MG glioblastoma cells in vitro.
- In vivo, radiolabeled 3H3 showed high retention at the tumor site in mice, while an irrelevant antibody cleared rapidly.
- Tumors that did not produce basic FGF did not retain the radiolabeled 3H3 antibody.
Conclusions:
- The 3H3 antibody, when radiolabeled, can specifically detect tumors that produce basic FGF.
- Scintigraphic imaging using 3H3 holds promise for identifying tumors suitable for antibody-based therapies.
- This technique could enhance the therapeutic application of anti-FGF antibodies in oncology.